Literature DB >> 34281467

Metformin for diabetes prevention: update of the evidence base.

Ulrike Hostalek1, Ian Campbell2.   

Abstract

We have conducted a narrative review based on a structured search strategy, focusing on the effects of metformin on the progression of non-diabetic hyperglycemia to clinical type 2 diabetes mellitus. The principal trials that demonstrated a significantly lower incidence of diabetes in at-risk populations randomized to metformin (mostly with impaired glucose tolerance [IGT]) were published mainly from 1999 to 2012. Metformin reduced the 3-year risk of diabetes by -31% in the randomized phase of the Diabetes Prevention Program (DPP), vs. -58% for intensive lifestyle intervention (ILI). Metformin was most effective in younger, heavier subjects. Diminishing but still significant reductions in diabetes risk for subjects originally randomized to these groups were present in the trial's epidemiological follow-up, the DPP Outcomes Study (DPPOS) at 10 years (-18 and -34%, respectively), 15 years (-18 and -27%), and 22 years (-18 and -25%). Long-term weight loss was also seen in both groups, with better maintenance under metformin. Subgroup analyses from the DPP/DPPOS have shed important light on the actions of metformin, including a greater effect in women with prior gestational diabetes, and a reduction in coronary artery calcium in men that might suggest a cardioprotective effect. Improvements in long-term clinical outcomes with metformin in people with non-diabetic hyperglycemia ("prediabetes") have yet to be demonstrated, but cardiovascular and microvascular benefits were seen for those in the DPPOS who did not vs. did develop diabetes. Multiple health economic analyses suggest that either metformin or ILI is cost-effective in a community setting. Long-term diabetes prevention with metformin is feasible and is supported in influential guidelines for selected groups of subjects. Future research will demonstrate whether intervention with metformin in people with non-diabetic hyperglycemia will improve long-term clinical outcomes.

Entities:  

Keywords:  Metformin; diabetes mellitus, type 2; glucose intolerance; prediabetic state

Year:  2021        PMID: 34281467     DOI: 10.1080/03007995.2021.1955667

Source DB:  PubMed          Journal:  Curr Med Res Opin        ISSN: 0300-7995            Impact factor:   2.580


  6 in total

1.  Metformin for Preventing Progression From Prediabetes to Diabetes Mellitus in People Living With Human Immunodeficiency Virus.

Authors:  Hataikarn Nimitphong; Sitta Jiriyasin; Pisekporn Kasemasawachanon; Somnuek Sungkanuparph
Journal:  Cureus       Date:  2022-04-27

2.  Metformin Protects against Spinal Cord Injury and Cell Pyroptosis via AMPK/NLRP3 Inflammasome Pathway.

Authors:  Yajiang Yuan; Xiangyi Fan; Zhanpeng Guo; Zipeng Zhou; Weiran Gao
Journal:  Anal Cell Pathol (Amst)       Date:  2022-03-27       Impact factor: 2.916

3.  Experimentally Induced Hyperinsulinemia Fails to Induce Polycystic Ovary Syndrome-like Traits in Female Rhesus Macaques.

Authors:  Rao Zhou; Cristin M Bruns; Ian M Bird; Joseph W Kemnitz; Daniel A Dumesic; David H Abbott
Journal:  Int J Mol Sci       Date:  2022-02-27       Impact factor: 5.923

Review 4.  Diabetes, Metformin and the Clinical Course of Covid-19: Outcomes, Mechanisms and Suggestions on the Therapeutic Use of Metformin.

Authors:  Clifford J Bailey; Mike Gwilt
Journal:  Front Pharmacol       Date:  2022-03-09       Impact factor: 5.810

5.  Fasting plasma glucose and HbA1c levels predict the risk of type 2 diabetes and diabetic retinopathy in a Thai high-risk population with prediabetes.

Authors:  Chaiwat Washirasaksiri; Weerachai Srivanichakorn; Nutsakol Borrisut; Tullaya Sitasuwan; Rungsima Tinmanee; Chayanis Kositamongkol; Pinyapat Ariyakunaphan; Chonticha Auesomwang; Naruemit Sayabovorn; Thanet Chaisathaphol; Pochamana Phisalprapa
Journal:  Front Pharmacol       Date:  2022-10-04       Impact factor: 5.988

6.  Discovery of the First in Class 9-N-Berberine Derivative as Hypoglycemic Agent with Extra-Strong Action.

Authors:  Mikhail V Khvostov; Elizaveta D Gladkova; Sergey A Borisov; Nataliya A Zhukova; Mariya K Marenina; Yuliya V Meshkova; Olga A Luzina; Tatijana G Tolstikova; Nariman F Salakhutdinov
Journal:  Pharmaceutics       Date:  2021-12-12       Impact factor: 6.321

  6 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.